Entinostat (MS-275)

For research use only. Not for use in humans.

目录号:S1053 别名: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275)强烈抑制HDAC1HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,抑制作用强于HDACs 4, 6, 8,和10。Entinostat可诱导自噬和凋亡。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 746.45 现货
RMB 466.83 现货
RMB 564.33 现货
RMB 1233.32 现货
RMB 2234.07 现货
RMB 6301.79 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Entinostat (MS-275)发表文献282篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Entinostat (MS-275)强烈抑制HDAC1HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,抑制作用强于HDACs 4, 6, 8,和10。Entinostat可诱导自噬和凋亡。Phase 3。
靶点
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外研究

MS-275通过作用于2′-氨基而抑制HDACs。MS-275作用于 K562细胞,诱导 p21WAF1/CIP1和凝溶胶蛋白的累积。MS-275作用于A2780细胞,可以降低S期细胞,提高G1期细胞。 MS-275通过抑制HAD而抑制人类肿瘤细胞系,包括 A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和 HCT-15细胞增殖, IC50 为41.5 nM到4.71 μM。[1]MS-275抑制HDACs,作用于HDAC1和 HDAC3时IC50 分别为0.51 μM和1.7 μM。而对其他的HDACs没有抑制效果,如HDAC4, 6, 8和10。[2]MS-275有效抑制人类白血病和淋巴癌细胞,包括U937, HL-60, K562, 和Jurkat。MS-275可以诱导U937细胞p21CIP1/WAF1 调节的生长和变异Marker (CD11b)的表达。MS-275降低cyclin D1和抗凋亡蛋白Mcl-1与XIAP的表达。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M336cWlEPTB;MD6wOlEh|ryP MmjvV2FPT0WU
ALL-PO M4jEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwME[zOVUh|ryP MXXTRW5ITVJ?
697 NH\XRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEm5O|Yh|ryP MnvQV2FPT0WU
NCI-H748 NYTiWnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMUCzN|Qh|ryP NGHJOmpUSU6JRWK=
NKM-1 M4i0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\mV2k4UUN3ME2wMlExQTF{IN88US=> NFPuS29USU6JRWK=
ES1 NEjhRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHkTWM2OD1yLkGxNlU2KM7:TR?= M4\FSXNCVkeHUh?=
NCI-H1963 M4Xwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[1cmlEPTB;MD6xNVU4QSEQvF2= NXT1RmtbW0GQR1XS
NCI-H1417 NWXGO3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\H[3NKSzVyPUCuNVI6PzRizszN NYrEbFg1W0GQR1XS
NEC8 NFjNfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXkb5RoUUN3ME2wMlE{PTJ5IN88US=> NYPUdmhuW0GQR1XS
CRO-AP2 NEDXNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMU[4PFkh|ryP NXP0TIFRW0GQR1XS
A3-KAW M2jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:wOIZKSzVyPUCuNVc3OjdizszN NUHlN|VFW0GQR1XS
SF539 NXzB[G1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf0R3NKSzVyPUCuNVk2QTNizszN M4XKRXNCVkeHUh?=
NOS-1 NVTR[JU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG4b4c2UUN3ME2wMlE6PjF7IN88US=> NF3oUZNUSU6JRWK=
NTERA-S-cl-D1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH6TWM2OD1yLkKwNVE{KM7:TR?= MkDlV2FPT0WU
COR-L88 NI[5R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ZN2lEPTB;MD6yNlk2QSEQvF2= NFXRU3hUSU6JRWK=
EM-2 NFjSN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXqbVhqUUN3ME2wMlI1ODd7IN88US=> NXLuSFg6W0GQR1XS
KARPAS-45 NFnENW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3QTWM2OD1yLkK3PFM{KM7:TR?= Mmn2V2FPT0WU
DSH1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvSZJmUUN3ME2wMlI5PzB6IN88US=> NUCzXHZEW0GQR1XS
HT-144 NYWxNGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLqTWM2OD1yLkOwNlU3KM7:TR?= NVPoTW95W0GQR1XS
ATN-1 NXvVXWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnSOoVVUUN3ME2wMlMxPTd4IN88US=> NEXuXpJUSU6JRWK=
HEL MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwM{GzOFgh|ryP NGjGPWZUSU6JRWK=
NB12 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ntNWlEPTB;MD6zNVc2PiEQvF2= MV;TRW5ITVJ?
LU-139 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiwNFNKSzVyPUCuN|M2OSEQvF2= MkLxV2FPT0WU
J-RT3-T3-5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxeIZKSzVyPUCuN|M4OTZizszN MWnTRW5ITVJ?
MOLT-13 NF;ofnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjYbW9KSzVyPUCuN|M5OSEQvF2= M4XZWnNCVkeHUh?=
SR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu4UoFKSzVyPUCuN|QzPjFizszN NUXJdJhSW0GQR1XS
CMK NXHoSGFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwM{W3Nlch|ryP NX3uXIZvW0GQR1XS
ES8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXHWHdKSzVyPUCuN|YxOjJizszN MljyV2FPT0WU
LB647-SCLC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqwe2dKSzVyPUCuN|Y4OyEQvF2= MlzrV2FPT0WU
TE-8 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W1UWlEPTB;MD6zOlk{PSEQvF2= MkHzV2FPT0WU
BV-173 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfYOHFKSzVyPUCuN|cyOjFizszN MYPTRW5ITVJ?
DEL NG\tcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ueG1KSzVyPUCuN|c1QDdizszN MULTRW5ITVJ?
ARH-77 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHD[HFKSzVyPUCuN|gyQTNizszN MYTTRW5ITVJ?
NCCIT NILMb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\PTWVYUUN3ME2wMlM5PjR7IN88US=> MUXTRW5ITVJ?
RPMI-8402 M3T2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPMTWM2OD1yLkO4O|AyKM7:TR?= M3rlenNCVkeHUh?=
MONO-MAC-6 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnIdWlKSzVyPUCuN|g4PzZizszN NEDsfW9USU6JRWK=
SK-MM-2 NVTUcFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DWTmlEPTB;MD6zPVg3QCEQvF2= NFHjS5ZUSU6JRWK=
CHP-126 NIPyd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHOTWM2OD1yLkSwNlMyKM7:TR?= MnPHV2FPT0WU
A101D MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmNJBKSzVyPUCuOFA{KM7:TR?= NGDISXpUSU6JRWK=
SCH MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XPcWlEPTB;MD60NFM1OiEQvF2= NFTiTJlUSU6JRWK=
NMC-G1 NYC0cYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXaTWM2OD1yLkSwN|Y4KM7:TR?= M4jSe3NCVkeHUh?=
NCI-H209 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4SzcGlEPTB;MD60NFYyOyEQvF2= MXzTRW5ITVJ?
MOLT-16 M{\XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PUSmlEPTB;MD60NVAyPyEQvF2= NGjqOZNUSU6JRWK=
RPMI-6666 NIiwc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHnTWM2OD1yLkSxNVIh|ryP NHrvdVFUSU6JRWK=
OPM-2 M3LDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDyTWM2OD1yLkSxOVE{KM7:TR?= MXnTRW5ITVJ?
MRK-nu-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH1U2s4UUN3ME2wMlQ{OTV|IN88US=> MnXKV2FPT0WU
BC-1 M3[wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0TWM2OD1yLkSzOFA{KM7:TR?= NX[1[YVWW0GQR1XS
MHH-NB-11 M121N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNEO0OVMh|ryP MVTTRW5ITVJ?
Ramos-2G6-4C10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwNEO4PVch|ryP NUDQ[JFCW0GQR1XS
LS-513 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvkUWd{UUN3ME2wMlQ1PTBzIN88US=> M4q1XXNCVkeHUh?=
K5 M3K5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNEewNlUh|ryP MkHIV2FPT0WU
HOP-62 NH;WSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwNEizOVgh|ryP MWHTRW5ITVJ?
NCI-H187 NIjVPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNEmyNlch|ryP MYXTRW5ITVJ?
BE-13 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnpRnd2UUN3ME2wMlQ6PjZzIN88US=> M3T3OXNCVkeHUh?=
HC-1 NFPOUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXpTWM2OD1yLkWwOFc{KM7:TR?= MX\TRW5ITVJ?
ACN NV:4V3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNUGwNlgh|ryP MnvrV2FPT0WU
HCC1599 M37rV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH4VlNtUUN3ME2wMlUyPTdizszN MXzTRW5ITVJ?
MV-4-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwNUOwOFEh|ryP M3GxdXNCVkeHUh?=
LC-2-ad M4HCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwNUO2OlMh|ryP MYLTRW5ITVJ?
HL-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLhTWM2OD1yLkW0NlYyKM7:TR?= M1\ybHNCVkeHUh?=
NB17 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwNUSzPEDPxE1? NIDVUYhUSU6JRWK=
TE-1 NGC4OJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnNTFVKSzVyPUCuOVU{ODZizszN MnTBV2FPT0WU
NCI-H524 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNUW0NFEh|ryP MUTTRW5ITVJ?
MZ7-mel NHPtcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrtS4RKSzVyPUCuOVYyODVizszN NIDWflhUSU6JRWK=
L-363 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhS4hKSzVyPUCuOVY3PTdizszN NFn4dnNUSU6JRWK=
BL-41 M4LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37FZ2lEPTB;MD61Olg5QSEQvF2= NUnUVmFmW0GQR1XS
LU-134-A M2TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPIRZJKSzVyPUCuOVcxPzNizszN NXzRfFhTW0GQR1XS
SIG-M5 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L0SmlEPTB;MD61O|g1QCEQvF2= NFnyN4dUSU6JRWK=
ONS-76 NX7ldGJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv0TWM2OD1yLkW4NlQzKM7:TR?= MmjTV2FPT0WU
KARPAS-299 NITDN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;O[oF1UUN3ME2wMlU5PTB2IN88US=> NXrBdVlHW0GQR1XS
DU-4475 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WxNmlEPTB;MD61PFcxOyEQvF2= MXTTRW5ITVJ?
NB69 NHntXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwNUm4NlUh|ryP M2XobHNCVkeHUh?=
MHH-PREB-1 NU[0bphWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTZUVJwUUN3ME2wMlYxPzF7IN88US=> MkTEV2FPT0WU
LU-165 NEHyeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHtTWM2OD1yLk[xPFEzKM7:TR?= NWDyPZFQW0GQR1XS
LOUCY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L6[GlEPTB;MD62N|M3PCEQvF2= MmHQV2FPT0WU
NCI-H526 M4LjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC5fJI5UUN3ME2wMlY{PTRzIN88US=> MYLTRW5ITVJ?
KE-37 M{HZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HhWGlEPTB;MD62OFI4PiEQvF2= NIHJWJdUSU6JRWK=
NALM-6 NXL3UmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNkS4OkDPxE1? Mo[1V2FPT0WU
CW-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXGcW9KSzVyPUCuOlU4QTRizszN M3\nTHNCVkeHUh?=
SU-DHL-1 NIW1NVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\oZmlEPTB;MD62OVk1PyEQvF2= NXX2UGZTW0GQR1XS
NB13 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHlboJKSzVyPUCuOlY5OTdizszN M4fONHNCVkeHUh?=
QIMR-WIL NEPjN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuTWM2OD1yLk[4N|Q{KM7:TR?= MkD4V2FPT0WU
ECC12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW0UpIxUUN3ME2wMlcxODh4IN88US=> MXHTRW5ITVJ?
KALS-1 NF;6WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPSb|VKSzVyPUCuO|A1QTJizszN MmfWV2FPT0WU
COR-L279 NHXKXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG2e2FnUUN3ME2wMlcxQTl4IN88US=> NWPBZnh7W0GQR1XS
NB14 M{DsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn1O2szUUN3ME2wMlczPjF5IN88US=> NV;MXoJjW0GQR1XS
CCRF-CEM MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LNNmlEPTB;MD63OFY3OSEQvF2= NFH5[oJUSU6JRWK=
SW954 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe0OmRwUUN3ME2wMlc2QTl7IN88US=> NGfjWZRUSU6JRWK=
IST-SL1 NHvPdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\3XXlNUUN3ME2wMlc4OzR6IN88US=> NXPrb2VqW0GQR1XS
LAMA-84 NIn0NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwN{e1Olch|ryP NHrQcVBUSU6JRWK=
Daudi NXXUPY14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rhUWlEPTB;MD63O|Y5OSEQvF2= NFznfHZUSU6JRWK=
BC-3 NIHXcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwN{izNFgh|ryP MWjTRW5ITVJ?
HCC2998 NUn3[VRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3nS3lqUUN3ME2wMlc5OzZizszN NVO4XYtnW0GQR1XS
NCI-H69 NIni[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml31TWM2OD1yLkiwNVQ4KM7:TR?= MkjMV2FPT0WU
CPC-N Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfnOXlKSzVyPUCuPFA2OjRizszN M1TCNXNCVkeHUh?=
NOMO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2yTWM2OD1yLkixNFg1KM7:TR?= MYTTRW5ITVJ?
CESS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwOEGxPVch|ryP M1:xfHNCVkeHUh?=
LC4-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n3ZmlEPTB;MD64OFAxPyEQvF2= NF35O5pUSU6JRWK=
BL-70 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHnTWM2OD1yLki1O|AzKM7:TR?= MX7TRW5ITVJ?
ES4 M4rGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfxbJZKSzVyPUCuPFU5PjhizszN MlzRV2FPT0WU
HCE-T MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonzTWM2OD1yLki3NVcyKM7:TR?= M{HuWHNCVkeHUh?=
JAR MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwOEe4Nlch|ryP M{XLb3NCVkeHUh?=
ST486 NXPMeHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf1TWM2OD1yLki3PVE4KM7:TR?= NELJfYhUSU6JRWK=
KS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK3UZNKSzVyPUCuPFgxQTZizszN M2\NZnNCVkeHUh?=
GDM-1 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwOEi2PFch|ryP NXK0U|lZW0GQR1XS
EHEB MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwOUK1PFUh|ryP NXywO5puW0GQR1XS
LB2518-MEL NGe4PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHvXHpzUUN3ME2wMlk{Ojh2IN88US=> NFfKVFFUSU6JRWK=
GOTO NGnmWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly4TWM2OD1yLkm1NFc3KM7:TR?= NEfMV5NUSU6JRWK=
LXF-289 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrT[XNKSzVyPUCuPVU6ODFizszN NIrNPZRUSU6JRWK=
ES6 NIHvdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLPV|ZLUUN3ME2wMlk3PDN5IN88US=> NH\1ZXlUSU6JRWK=
OS-RC-2 NF\Bb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwOU[4N{DPxE1? MmSyV2FPT0WU
DMS-153 M1TRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP0SXdKSzVyPUCuPVc1PjlizszN NFzNNWhUSU6JRWK=
SK-PN-DW NXrY[YczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn23TWM2OD1yLkm3PFMyKM7:TR?= NFTsUJZUSU6JRWK=
HH Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO3Npk5UUN3ME2wMlk5QTV7IN88US=> NGHYNWpUSU6JRWK=
SH-4 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELzOIJKSzVyPUGuNFI1OSEQvF2= NUe5fIM1W0GQR1XS
MOLT-4 NHLlb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LqPGlEPTB;MT6wN|Q2PCEQvF2= M2\aTnNCVkeHUh?=
TGW NHzQdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwMEe2O|Uh|ryP M4KxU3NCVkeHUh?=
L-540 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\0TWM2OD1zLkGwOlA1KM7:TR?= NGXvZplUSU6JRWK=
PF-382 NVL5bIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX5VGxYUUN3ME2xMlEyPTF|IN88US=> NUTudlB3W0GQR1XS
LC-1F M4n0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFwMUKwNFch|ryP MkS5V2FPT0WU
OVCAR-4 NX64dm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom4TWM2OD1zLkGzNVY2KM7:TR?= NWTKPIFzW0GQR1XS
A4-Fuk MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwMUWzOlQh|ryP NVjobIxGW0GQR1XS
HCC2218 NEe4Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMU[2OFEh|ryP M3rNfXNCVkeHUh?=
HAL-01 NHnrSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMU[5OFMh|ryP MWjTRW5ITVJ?
IST-MEL1 NUjsUZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMUe2OVkh|ryP NGHtVndUSU6JRWK=
NCI-H719 NX33XHNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrEUphKSzVyPUGuNVc5QThizszN MYDTRW5ITVJ?
EVSA-T NULicmMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ubmlEPTB;MT6xPFEyPCEQvF2= NIPCOoxUSU6JRWK=
SK-NEP-1 NVm3VJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwMkCyOlYh|ryP Mkm1V2FPT0WU
OCUB-M NV\lWXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXZNG5KSzVyPUGuNlE1QDlizszN M1\INnNCVkeHUh?=
MEG-01 NUPqNXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzndYdFUUN3ME2xMlIzOTF6IN88US=> M{HVdXNCVkeHUh?=
no-10 M4DNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3UTWM2OD1zLkKzNVEzKM7:TR?= NW\OT2RzW0GQR1XS
MHH-CALL-2 NVKxNm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSyTWM2OD1zLkK0O|IyKM7:TR?= MXvTRW5ITVJ?
SK-N-DZ MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;4R4tzUUN3ME2xMlI1Pzd4IN88US=> M2LIZnNCVkeHUh?=
SCLC-21H MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD1zLkK2OFc5KM7:TR?= MmDnV2FPT0WU
CTV-1 NW\wWFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXqSGlLUUN3ME2xMlI4PDJ3IN88US=> NUSwW|YyW0GQR1XS
NB1 M1G2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID1T4ZKSzVyPUGuNlc4OzJizszN MlfQV2FPT0WU
NCI-H64 M2\leWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn5bHhKSzVyPUGuNlg1PjJizszN MWPTRW5ITVJ?
MDA-MB-134-VI NXTsOFlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYcY9KSzVyPUGuNlg2PzdizszN NYX2RoFuW0GQR1XS
LB2241-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTHVY5mUUN3ME2xMlI5PjZ|IN88US=> NIO3[4dUSU6JRWK=
8-MG-BA Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP6cYxKSzVyPUGuNlg5PjZizszN MnzVV2FPT0WU
LP-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTueYZ3UUN3ME2xMlI6QTR5IN88US=> Mn:2V2FPT0WU
LS-411N M3XpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XCW2lEPTB;MT6zNFk6QCEQvF2= NH\qTnNUSU6JRWK=
CAL-148 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33uU2lEPTB;MT6zNlU1OiEQvF2= M36xZ3NCVkeHUh?=
NCI-H2171 NHH5eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PSUGlEPTB;MT6zOFUxOiEQvF2= M4jvW3NCVkeHUh?=
JiyoyeP-2003 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwM{WzPUDPxE1? M1TDNHNCVkeHUh?=
NCI-H2107 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnaPJQ2UUN3ME2xMlM2QDh|IN88US=> M2X6TnNCVkeHUh?=
BB30-HNC NVK5fYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLFd3I6UUN3ME2xMlM5QTd6IN88US=> NVnDOo1mW0GQR1XS
K-562 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rOmdKSzVyPUGuN|kzOTlizszN MnX1V2FPT0WU
PSN1 NHTXPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTwbXBKSzVyPUGuOFIzQDdizszN NG\DbpdUSU6JRWK=
HCC2157 NXf5NGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzoN5NKSzVyPUGuOFI3QTFizszN M4nubHNCVkeHUh?=
SBC-1 NGLYUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\tTIpKSzVyPUGuOFI4PDFizszN M{Tie3NCVkeHUh?=
MC116 NF[yN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwNEO2NVUh|ryP NYHiWFY4W0GQR1XS
KARPAS-422 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzMV|NJUUN3ME2xMlQ2OzV6IN88US=> NXnXSolCW0GQR1XS
LB996-RCC NV3zPZJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D6WmlEPTB;MT60O|ExOyEQvF2= NUTSVWtwW0GQR1XS
MSTO-211H NU\2ZVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzrVWJKSzVyPUGuOFc6QDdizszN M4qwfXNCVkeHUh?=
BT-474 M32yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3VXINKSzVyPUGuOVE4PjRizszN NUTBOllxW0GQR1XS
A388 NV24[HhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwNUG5OFUh|ryP NFvlNXpUSU6JRWK=
SJSA-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O1NWlEPTB;MT61NlI3KM7:TR?= MkDiV2FPT0WU
COLO-829 M4Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LvRWlEPTB;MT61N|U3PCEQvF2= M1rvbHNCVkeHUh?=
KM-H2 M3vVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwNU[2O{DPxE1? MVzTRW5ITVJ?
GR-ST MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6eGlEPTB;MT61OlgzKM7:TR?= NI\wS3dUSU6JRWK=
RPMI-8866 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqd2lsUUN3ME2xMlYxOTR2IN88US=> MXPTRW5ITVJ?
KG-1 NXfHelE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;vbINKSzVyPUGuOlE6ODFizszN M{XzS3NCVkeHUh?=
NCI-H82 NV7QPGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLObWpKSzVyPUGuOlM1ODZizszN NU[3XGZNW0GQR1XS
LB1047-RCC NXLvR|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInmeFNKSzVyPUGuOlM1PTlizszN M{f4TXNCVkeHUh?=
KM12 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHKdFBKSzVyPUGuOlQ4KM7:TR?= NUT4fJpZW0GQR1XS
NB5 NG[3eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HmWGlEPTB;MT62OVY4PyEQvF2= NGq0fFRUSU6JRWK=
HDLM-2 NVHybYNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXvZmNKSzVyPUGuOlgzQDFizszN M4G4dnNCVkeHUh?=
KU812 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwNkm2NFUh|ryP MXvTRW5ITVJ?
DB M3LOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKydYFKSzVyPUGuO|A{PTNizszN NGX2VoRUSU6JRWK=
HD-MY-Z MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwN{WyN|Qh|ryP MXrTRW5ITVJ?
KURAMOCHI NXTaNXZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHpTWM2OD1zLke3NlA4KM7:TR?= MWTTRW5ITVJ?
ETK-1 M{nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm5TWM2OD1zLke4PFc6KM7:TR?= MoriV2FPT0WU
SK-UT-1 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnES2VqUUN3ME2xMlc6Ozh6IN88US=> Mkm1V2FPT0WU
HUTU-80 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjoTWM2OD1zLke5OVA5KM7:TR?= NYnh[VdPW0GQR1XS
ES7 NIK2Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfLfIhKSzVyPUGuPFA{ODJizszN MX;TRW5ITVJ?
SW872 NXvSNmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwOEGzPVUh|ryP MXTTRW5ITVJ?
TK10 NGf3NHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnZTWM2OD1zLkizNVA5KM7:TR?= NFHweXVUSU6JRWK=
LB831-BLC NFnSRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HFVmlEPTB;MT64N|U3OyEQvF2= M{nNTnNCVkeHUh?=
TE-9 M4HpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLvNZpMUUN3ME2xMlg1PDJ{IN88US=> NID4SI9USU6JRWK=
MLMA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\TfXdKSzVyPUGuPFgzOzRizszN NIr1cmdUSU6JRWK=
D-542MG NYPBdHBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu0cGtwUUN3ME2xMlg6Ozd|IN88US=> MULTRW5ITVJ?
EW-16 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFwOUK3NkDPxE1? NXmwTpdXW0GQR1XS
LOXIMVI MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwOUOyPEDPxE1? MWHTRW5ITVJ?
GB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTXTWM2OD1zLkmzPFY3KM7:TR?= NEXHZ3VUSU6JRWK=
IST-SL2 NUnGXll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOzfG5KSzVyPUKuNFAzPjJizszN NUfxU25VW0GQR1XS
LAN-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXlenU3UUN3ME2yMlAyQTZ4IN88US=> Ml7EV2FPT0WU
NCI-H510A NVWxXJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwMES1NFIh|ryP NXr4RlhMW0GQR1XS
NCI-H1092 M1jsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJwMEWxNlQh|ryP Mn3xV2FPT0WU
HT M{PKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrtZZNKSzVyPUKuNVA1PTRizszN NULpPY1HW0GQR1XS
RL95-2 NHPDXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwMUG0PFIh|ryP NGP2ZWVUSU6JRWK=
NCI-H1355 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHraXYdKSzVyPUKuNVE4QTJizszN MnfWV2FPT0WU
NCI-H720 NVjpc|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwMU[4O|Mh|ryP MmDIV2FPT0WU
NCI-H1522 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonETWM2OD1{LkKxO|I{KM7:TR?= MWjTRW5ITVJ?
LB373-MEL-D NHKyTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1{LkK2PVAzKM7:TR?= M{n6[3NCVkeHUh?=
DG-75 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJwMkexOFgh|ryP NEXUTodUSU6JRWK=
ML-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3GTWM2OD1{LkOyPFU2KM7:TR?= MYLTRW5ITVJ?
SF126 NXXiNGZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\XWJNKSzVyPUKuN|MxQTRizszN M13ZbnNCVkeHUh?=
MPP-89 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS3TWM2OD1{LkOzNVQ2KM7:TR?= NFq4WItUSU6JRWK=
NCI-H345 NGfpclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr2TWM2OD1{LkOzNlc4KM7:TR?= NI\mcWZUSU6JRWK=
LS-123 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTPZ5JzUUN3ME2yMlM1QTN4IN88US=> M3\NVXNCVkeHUh?=
NB10 MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7RTWM2OD1{LkSxNFkzKM7:TR?= MoPRV2FPT0WU
CGTH-W-1 M{fPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYiwXWhPUUN3ME2yMlQzOjZ5IN88US=> NGDXSWhUSU6JRWK=
CP66-MEL NX;vcJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTqbVBpUUN3ME2yMlQ4PzdizszN MXvTRW5ITVJ?
L-428 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXMUlVlUUN3ME2yMlQ5PTJzIN88US=> Ml3UV2FPT0WU
DMS-79 NWW2[HJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPubo9KSzVyPUKuOVQyODNizszN M4HEV3NCVkeHUh?=
NCI-H1882 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2bWlEPTB;Mj62O|U3OiEQvF2= M33jWHNCVkeHUh?=
KGN M3jRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\uTWM2OD1{Lke2PFc3KM7:TR?= NYHSRnRRW0GQR1XS
EW-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPXcm5pUUN3ME2yMlc4ODh|IN88US=> MVLTRW5ITVJ?
U-266 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;PemlEPTB;Mj64OFgzOyEQvF2= NHPGR|hUSU6JRWK=
COLO-320-HSR NHLLXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PHbmlEPTB;Mj64OVY1OSEQvF2= NULlOlNUW0GQR1XS
KMOE-2 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJwOEe3NVEh|ryP Ml7YV2FPT0WU
BB49-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXrTWM2OD1{LkmyOFgh|ryP NYPhWZhIW0GQR1XS
GI-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXoTWM2OD1{LkmyPVU4KM7:TR?= M4jI[3NCVkeHUh?=
NCI-H1304 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwMEC1NVEh|ryP M{\pXXNCVkeHUh?=
NCI-H2227 NWPnbWlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLLS3BKSzVyPUOuNFIxPzlizszN MWjTRW5ITVJ?
U-87-MG Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwMEO1NVMh|ryP MnW2V2FPT0WU
NCI-H747 NU\GO5dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXyTplKSzVyPUOuNFUzODZizszN NIPqfHhUSU6JRWK=
CTB-1 M3H5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jtUWlEPTB;Mz6wOVM4PiEQvF2= NVrRU|c{W0GQR1XS
RPMI-8226 NWTPbWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4na[mlEPTB;Mz6xOFM4QCEQvF2= MmPFV2FPT0WU
NCI-H2141 NHzVbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\DRWlEPTB;Mz6xOlU3PiEQvF2= NH7G[5dUSU6JRWK=
IST-MES1 NVTjToN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGiyeGFKSzVyPUOuNVgzPzlizszN NXHSRlQ4W0GQR1XS
TE-5 NUm3cmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXOe3JKSzVyPUOuNlE{PDJizszN MnrnV2FPT0WU
UACC-257 M2Dne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwNEO2OVkh|ryP MmHyV2FPT0WU
SK-N-FI MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPLW5NQUUN3ME2zMlQ2OjJ5IN88US=> NW\pZ|FMW0GQR1XS
MFH-ino MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u3fGlEPTB;Mz60OlU5QSEQvF2= MnPnV2FPT0WU
SF268 NH3yfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzKZlk3UUN3ME2zMlQ5OTd2IN88US=> NEDwSIhUSU6JRWK=
TE-12 NEnMfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nzVWlEPTB;Mz61NVY6QSEQvF2= MY\TRW5ITVJ?
NB6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwNUW1OlMh|ryP NYXZPYRmW0GQR1XS
DJM-1 M17wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q5RWlEPTB;Mz61PVg6QSEQvF2= M1nVNnNCVkeHUh?=
MZ1-PC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzPTWM2OD1|Lk[xOlI1KM7:TR?= NVrNNoE3W0GQR1XS
OCI-AML2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly1TWM2OD1|Lk[yOlcyKM7:TR?= NGXOOlhUSU6JRWK=
NCI-H1155 NI\4S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTCd2l3UUN3ME2zMlcxQTR5IN88US=> MXXTRW5ITVJ?
RKO Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPMNo1wUUN3ME2zMlc4OTh7IN88US=> MYDTRW5ITVJ?
ECC4 NUToW4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rtZWlEPTB;Mz65O|E6PSEQvF2= Mn3EV2FPT0WU
BB65-RCC NWHFWGVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwOUe1OFch|ryP MWHTRW5ITVJ?
EB-3 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlZ3NKSzVyPUOuPVk3OzNizszN NWDGXmhNW0GQR1XS
SHP-77 M{nLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm0TWM2OD12LkCwOVI1KM7:TR?= NYTHS41HW0GQR1XS
NCI-H2196 NWm0WWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPPTWM2OD12LkC1OlI2KM7:TR?= M3nYT3NCVkeHUh?=
GI-ME-N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjzV4lKSzVyPUSuNFY{QTlizszN NVXDV4l2W0GQR1XS
MN-60 M3\pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG4fnZ4UUN3ME20MlExQDdizszN M1LQV3NCVkeHUh?=
NCI-H1694 NGX4NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2O4ZKSzVyPUSuNVM1ODVizszN Mm[5V2FPT0WU
LU-65 NWfUcFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHSTWM2OD12LkG1N|MzKM7:TR?= NXzsSWRYW0GQR1XS
NCI-H1436 NFrsSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRwMUizN|Mh|ryP MlPLV2FPT0WU
KINGS-1 M1zIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nTdGlEPTB;ND6zNVQ{OiEQvF2= MkXBV2FPT0WU
GT3TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzIfmJKSzVyPUSuN|MzPjhizszN M{S0ZXNCVkeHUh?=
Becker NX21OXlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jHTWlEPTB;ND6zO|MyOiEQvF2= MVvTRW5ITVJ?
HCC1187 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnToTWM2OD12Lki5OlU4KM7:TR?= NEDKNXVUSU6JRWK=
D-502MG NX\EfHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\3XJZlUUN3ME21MlAxPDF4IN88US=> NUnTdmZwW0GQR1XS
VA-ES-BJ MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njOWlEPTB;NT6xN|c4QCEQvF2= MUPTRW5ITVJ?
NB7 NIDBVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTVwMUSxNVIh|ryP NG\ubI9USU6JRWK=
SW962 NGDtZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPFTWM2OD13LkO4PFE1KM7:TR?= Ml\LV2FPT0WU
no-11 M370U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfFOGFKSzVyPUWuO|Y{PDNizszN Mm\hV2FPT0WU
KNS-81-FD MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rGWGlEPTB;NT65NFY6PCEQvF2= NVfOTlR3W0GQR1XS
COLO-684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfjTWM2OD13Lkm5OFk1KM7:TR?= NFvSTndUSU6JRWK=
D-263MG NFrrTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrJ[VZkUUN3ME22MlA5QDl3IN88US=> NHjTNmxUSU6JRWK=
EW-24 M33yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZwMki1NUDPxE1? NWHPdGsyW0GQR1XS
TE-10 NGG4U|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofTTWM2OD14LkSyOlI{KM7:TR?= MXLTRW5ITVJ?
EKVX MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnDTGJKSzVyPU[uOFY{OjFizszN NF7oNmtUSU6JRWK=
NCI-H1648 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvETWM2OD14Lk[3OVU4KM7:TR?= NEjSfXhUSU6JRWK=
LB771-HNC M1HIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTZwOUKzNFEh|ryP MWrTRW5ITVJ?
SK-MEL-1 M3nDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRThwMUOxOlYh|ryP M1vWRXNCVkeHUh?=
COLO-668 NGjzW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHPU5pKSzVyPUiuNlc4QDZizszN M1HOTXNCVkeHUh?=
EW-12 M{TrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwNEC4NFMh|ryP NELrW5dUSU6JRWK=
A253 NIPzboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRThwOES2OlEh|ryP M1H6VnNCVkeHUh?=
NCI-H2126 NVjwVmluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M163c2lEPTB;OD64PVMyQSEQvF2= MU\TRW5ITVJ?
Calu-6 NYj3[lJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rqOGlEPTB;OD65PVA1OiEQvF2= NGLJdlFUSU6JRWK=
NCI-H23 MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTlwMUe3OFYh|ryP MnrhV2FPT0WU
WSU-NHL M2LXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLaRXlKSzVyPUmuO|c1PzhizszN M4K5SHNCVkeHUh?=
MMAC-SF M2TKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjYNJRjUUN3ME25Mlk4QTB2IN88US=> Mk\TV2FPT0WU
SK-LMS-1 M4PlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hqd2lEPTB;MUCuNlg{PCEQvF2= M3XTOXNCVkeHUh?=
GCIY MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfHTWM2OD1zMD61PVI1KM7:TR?= NYCyZ4JuW0GQR1XS
TE-15 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1zMT62NFA1KM7:TR?= NFTjSZlUSU6JRWK=
EoL-1-cell NWHKfIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFzLke2PFIh|ryP M3PlW3NCVkeHUh?=
NCI-H2081 MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPkTWM2OD1zMT63O|g3KM7:TR?= MYHTRW5ITVJ?
EW-3 M2\GcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDJTWM2OD1zMj6yOFY{KM7:TR?= NUDoUlBKW0GQR1XS
CAS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfUTWM2OD1zMj6zOlMyKM7:TR?= NWfxOopkW0GQR1XS
C2BBe1 NYi0cWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnWTWM2OD1zMj62NVMyKM7:TR?= NX3j[4lFW0GQR1XS
D-247MG NHzpUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T4dmlEPTB;MUKuO|k2OiEQvF2= NHvMelRUSU6JRWK=
NCI-SNU-5 NWC5XplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF{LkiwNVMh|ryP MYrTRW5ITVJ?
LS-1034 NWrtWWszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvvW4ZDUUN3ME2xOE4{QTd3IN88US=> MlrtV2FPT0WU
EW-18 NXixN4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHQe292UUN3ME2xOE41PDhizszN NWLhbFhDW0GQR1XS
Raji NITpTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfX[IFKSzVyPUG0MlUxPDlizszN MmT6V2FPT0WU
D-283MED NV;3NotoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;R[opKUUN3ME2xOE43OjdzIN88US=> NG\NNHRUSU6JRWK=
MZ2-MEL Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fPfmlEPTB;MUSuPVY6PiEQvF2= MXPTRW5ITVJ?
NCI-SNU-16 M1e5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLKSIFKSzVyPUG1MlQ3OzNizszN MoK3V2FPT0WU
P30-OHK M3y0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu4TWM2OD1zNz63PFMyKM7:TR?= MUPTRW5ITVJ?
RXF393 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF7LkCxPFYh|ryP NG\DU4pUSU6JRWK=
NCI-H1395 NInuNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXZXWhxUUN3ME2yNE43PzB|IN88US=> NXzHdFdyW0GQR1XS
U-698-M NIPNbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJyLkewO|Uh|ryP NFPOUVZUSU6JRWK=
NCI-SNU-1 M33Pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHmS|ViUUN3ME2yNE44OjJ|IN88US=> NFHJXYxUSU6JRWK=
SW684 NXW5N4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32wfGlEPTB;MkGuNVcyPiEQvF2= NUfNWHZEW0GQR1XS
NCI-H716 NYnzOldIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0b2lEPTB;MkGuN|E2PCEQvF2= Ml;wV2FPT0WU
JVM-2 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJzLkSxN|Mh|ryP NFy3[5JUSU6JRWK=
NCI-H1581 M4jMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;6[nA3UUN3ME2yNk41OTR6IN88US=> NIHFdJlUSU6JRWK=
CA46 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rLd2lEPTB;M{GuOlk{PiEQvF2= NYnkbXNzW0GQR1XS
SNB75 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN|Lk[1NFMh|ryP NEHS[HNUSU6JRWK=
KNS-42 M1rlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN3Lkm2NlQh|ryP NVryPGxHW0GQR1XS
TUR MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN4LkC1NlEh|ryP MXTTRW5ITVJ?
REH M4HIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjOTWM2OD1|Nz64NlEyKM7:TR?= M{[5U3NCVkeHUh?=
EW-22 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3hTWM2OD12Mj6yPFg2KM7:TR?= NWi3[JpwW0GQR1XS
NCI-H446 NG\OT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR{Lke4OVMh|ryP M17aUXNCVkeHUh?=
ES3 M1viUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jCTWlEPTB;NEOuNVM{QSEQvF2= NH7uZXRUSU6JRWK=
EW-11 NImzPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR2LkiyNVgh|ryP M2D0dXNCVkeHUh?=
RH-1 M2\3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXLVI55UUN3ME20O{42QDF{IN88US=> MlS0V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
体内研究 MS-275按49 mg/kg剂量作用于除了HCT-15的人类移植瘤都显示出强抗癌活性。[1]MS-275促进恶性实体瘤和恶性血液病的治疗可能性,及生理和畸变基因表达的调节。[4]MS-275和IL-2联用,作用于肾细胞癌显示出强抗癌活性,因为降低调节性T细胞和增强脾细胞的表达。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[6]
- 合并

标准HDAC实验:

用HDAC buffer按1:6稀释鼠肝内的酶。重组人类HDACs按1:4稀释在HDAC buffer中。用于标准HDAC实验,60 μl HDAC buffer和10 μl 稀释的酶溶液在30oC混合。在HDAC buffer中加入30 μl基底液开始HDAC反应,随后在30oC下温育30分钟。加入100 μl胰蛋白酶溶液终止反应,胰蛋白酶溶液由溶于50 mM Tris-HCl(pH 为8.0)的10 mg/ml 胰蛋白酶, 100 mM NaCl,及 2 μM TSA组成。30oC下温育20分钟, 通过测定460纳米(λex = 390 nm)处的荧光监测AMC的释放。使用释放的AMC校准荧光强度 。用于标准时间过程实验,在初始100 μl HDAC 反应中加入20 pmol 基底物。2-50 pmol 基底物的酶法分析产物获得荧光AMC,通过测量这种荧光AMC来测定 Km值和 Vmax值。使用Hanes 图分析实验数据。记录的AMC信号是针对没有酶而有buffer和基底物的空白区。
细胞实验:[2]
- 合并
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和HCT-15细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 3天
  • Method: 5×103个肿瘤细胞接种到96孔板上,加入梯度浓度MS-275培养三天。细胞用0.1 mg/mL中性红在CO2反应器中染色1小时,测定中性红与50 μL乙醇和150 μL 0.1 M Na2HPO4溶解后的OD540,测定IC50值。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 侧腹皮下注射A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1和Calu-3细胞的裸鼠
  • Dosages: 12.3, 24.5和49 mg/kg
  • Administration: 每天口服处理一次,每周进行5天,持续4周。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 376.41
化学式

C21H20N4O3

CAS号 209783-80-2
储存条件 粉状
溶于溶剂
别名 SNDX-275

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Entinostat (MS-275) | Entinostat (MS-275)供应商 | 采购Entinostat (MS-275) | Entinostat (MS-275)价格 | Entinostat (MS-275)生产 | 订购Entinostat (MS-275) | Entinostat (MS-275)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID